Your browser doesn't support javascript.
loading
The NCI-MATCH trial: lessons for precision oncology.
O'Dwyer, Peter J; Gray, Robert J; Flaherty, Keith T; Chen, Alice P; Li, Shuli; Wang, Victoria; McShane, Lisa M; Patton, David R; Tricoli, James V; Williams, P Mickey; Iafrate, A John; Sklar, Jeffrey; Mitchell, Edith P; Takebe, Naoko; Sims, David J; Coffey, Brent; Fu, Tony; Routbort, Mark; Rubinstein, Larry V; Little, Richard F; Arteaga, Carlos L; Marinucci, Donna; Hamilton, Stanley R; Conley, Barbara A; Harris, Lyndsay N; Doroshow, James H.
Afiliación
  • O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA, USA. peter.odwyer@pennmedicine.upenn.edu.
  • Gray RJ; Dana-Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA, USA.
  • Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
  • Li S; Dana-Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA, USA.
  • Wang V; Dana-Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA, USA.
  • McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
  • Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD, USA.
  • Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
  • Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Iafrate AJ; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Sklar J; Yale University, New Haven, CT, USA.
  • Mitchell EP; Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Takebe N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
  • Sims DJ; Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Coffey B; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD, USA.
  • Fu T; Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Routbort M; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
  • Little RF; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
  • Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USA.
  • Marinucci D; ECOG-ACRIN Cancer Research Group, Philadelphia, PA, USA.
  • Hamilton SR; City of Hope National Medical Center, Duarte, CA, USA.
  • Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
  • Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
  • Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Nat Med ; 29(6): 1349-1357, 2023 Jun.
Article en En | MEDLINE | ID: mdl-37322121
ABSTRACT
The NCI-MATCH (Molecular Analysis for Therapy Choice) trial ( NCT02465060 ) was launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial-largely for patients with treatment-refractory, malignant solid tumors. Having completed in 2023, it remains one of the largest tumor-agnostic, precision oncology trials undertaken to date. Nearly 6,000 patients underwent screening and molecular testing, with a total of 1,593 patients (inclusive of continued accrual from standard next-generation sequencing) being assigned to one of 38 substudies. Each substudy was a phase 2 trial of a therapy matched to a genomic alteration, with a primary endpoint of objective tumor response by RECIST criteria. In this Perspective, we summarize the outcomes of the initial 27 substudies in NCI-MATCH, which met its signal-seeking objective with 7/27 positive substudies (25.9%). We discuss key aspects of the design and operational conduct of the trial, highlighting important lessons for future precision medicine studies.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos